Asensus Surgical Inc (ASXC)
0.3479
0.00 (0.00%)
Previous Close | 0.3479 |
---|---|
Open | - |
Bid | 0.3461 |
Ask | 0.4500 |
Day's Range | N/A - N/A |
52 Week Range | 0.1690 - 0.3479 |
Volume | 0 |
Market Cap | 94.74M |
PE Ratio (TTM) | -4.970 |
EPS (TTM) | -0.1 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | - |
News & Press Releases
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ASXC stock results show that Asensus Surgical missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 13, 2024
![](https://investorplace.com/wp-content/uploads/2021/09/robotics-hands-1600.jpg)
Discover key robotics stocks to buy now for Q3. Learn about industry leaders in autonomous vehicles, robotic surgery and IoT integration.
Via InvestorPlace · July 17, 2024
![](https://ml.globenewswire.com/media/54cbaf70-16fe-4ac1-8956-c2d21ff8ae45/small/firm-logo-with-investor-law-firm-jpg.jpg)
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · June 13, 2024
![](https://mms.businesswire.com/media/20240612164665/en/1919461/22/Latest_KSF_M%26A.jpg)
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Asensus Surgical, Inc. (NYSEASXC) to KARL STORZ Endoscopy-America, Inc. Under the terms of the proposed transaction, shareholders of Asensus will receive $0.35 in cash for each share of Asensus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
By Kahn Swick & Foti, LLC · Via Business Wire · June 13, 2024
![](https://cdn.benzinga.com/files/images/story/2024/06/07/Penang--Malaysia---Feb-2--2021-Gamestop-_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 7, 2024
![](https://cdn.benzinga.com/files/images/story/2024/06/07/ASXC.png?width=1200&height=800&fit=crop)
KARL STORZ Endoscopy-America has agreed to acquire Asensus Surgical for $0.35 per share, representing a 67% premium. This acquisition will bolster KARL STORZ's robotic surgical market presence.
Via Benzinga · June 7, 2024
![](https://mms.businesswire.com/media/20240607734559/en/1567526/5/Firm_Logo-with_Investor_Law_Firm.jpg)
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Asensus Surgical, Inc. (NYSE American: ASXC) to KARL STORZ Endoscopy-America, Inc. for $0.35 per share in cash is fair to Asensus shareholders.
By Halper Sadeh LLC · Via Business Wire · June 7, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 4, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ASXC stock results show that Asensus Surgical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 14, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 3, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 1, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/04/wayfair_-_logo.jpg?width=1200&height=800&fit=crop)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · April 4, 2024
![](https://investorplace.com/wp-content/uploads/2022/03/penny-stocks-1024x576.png)
These three penny stocks certainly look well-positioned to ride the next wave of growth higher in their diverse market niches.
Via InvestorPlace · April 3, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ASXC stock results show that Asensus Surgical beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 21, 2024
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • Creative Realities (NASDAQCREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via Benzinga · March 21, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 26, 2024
![](https://investorplace.com/wp-content/uploads/2022/07/healthcare-1600.jpg)
Thanks to the permanent relevance of medical innovations, investors ought to consider looking at these healthcare stocks.
Via InvestorPlace · January 17, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 9, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 5, 2024
![](https://investorplace.com/wp-content/uploads/2022/06/tech-stocks-1600.png)
With the innovation machinery running at full speed, investors may want to target these ideas for hottest tech stocks of 2024.
Via InvestorPlace · January 4, 2024